Welcome to our dedicated page for Cyclacel Phar Pr SEC filings (Ticker: CYCCP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking Cyclacel Pharmaceuticals’ next clinical milestone can feel like hunting for needles in a 300-page stack of SEC disclosures. The company’s filings brim with dense oncology science—CDK2/9 dosing data for fadraciclib, PLK1 safety cohorts for plogosertib—and intricate financing terms tied to its CYCCP preferred shares. Finding trial timelines, cash runway, or Cyclacel Pharmaceuticals insider trading Form 4 transactions shouldn’t require a PhD or hours of scrolling.
Stock Titan closes that gap. Our platform delivers AI-powered summaries that turn every 10-K, 10-Q, 8-K, or S-3 into plain English bullet points, then links you straight to the source page. Whether you search “Cyclacel Pharmaceuticals quarterly earnings report 10-Q filing” or “understanding Cyclacel Pharmaceuticals SEC documents with AI,” you’ll see trial costs, dilution impact, and risk factors highlighted in context. Real-time alerts surface Cyclacel Pharmaceuticals Form 4 insider transactions real-time, so you know the moment executives buy or sell.
Wondering where the next catalyst hides? Use our quick-view cards to jump to:
- 10-K & 10-Q – cash runway, R&D spend, and drug pipeline status in one click (Cyclacel Pharmaceuticals annual report 10-K simplified).
- 8-K – trial data drops and financing deals (Cyclacel Pharmaceuticals 8-K material events explained).
- Form 4 – executive stock moves (Cyclacel Pharmaceuticals executive stock transactions Form 4).
- DEF 14A – Cyclacel Pharmaceuticals proxy statement executive compensation snapshots.
No more decoding biotech jargon—just actionable insights like Cyclacel Pharmaceuticals earnings report filing analysis delivered as soon as the document hits EDGAR. Explore every CYCCP disclosure, clarified and searchable, today.
Cyclacel Pharmaceuticals (CYCCP) filed a DEFA14A Amendment No. 1 to its 2025 proxy statement.
The sole revision corrects total shares outstanding on the May 1, 2025 record date from 381,202,294 to 356,357,531. No other sections, proposals or compensation disclosures were modified. All previously distributed proxy materials and voting matters remain unchanged for the virtual annual meeting scheduled on June 30, 2025.
Cyclacel Pharmaceuticals, Inc. (CYCC/CYCCP) filed an 8-K announcing a private placement of Series F Convertible Preferred Stock and accompanying warrants that closed on 20 June 2025. The company entered into a Securities Purchase Agreement with accredited investors for 3 million shares of Series F Preferred Stock at $1.00 per share, generating $3.0 million in gross proceeds to be used for general corporate and operating purposes.
Dilution mechanics: Each preferred share converts into 3.27 common shares, implying an effective conversion price of roughly $0.31 per common share. Full conversion would create up to ≈9.81 million new common shares, subject to a 4.99 % ownership cap per investor until stockholder approval is obtained. In addition, investors received 29.43 million five-year warrants split into three tranches with exercise prices of $0.51 (Series A), $0.60 (Series B) and $0.68 (Series C) per share. The warrants and preferred shares were issued under Regulation S and are therefore unregistered.
Governance & rights: The Series F Preferred votes with common stock on an as-converted basis (subject to the ownership cap), participates in common dividends, and carries a $1.00 per-share liquidation preference pari passu with other preferred stock. The company has committed to seek stockholder approval for the full issuance of common shares underlying the preferred and the warrants to comply with Nasdaq rules.
Key implications: The financing provides near-term liquidity but introduces the potential for significant future share dilution—up to ~39.2 million additional common shares if all instruments are exercised/converted. Investor approval risk, dilution magnitude, and relatively low effective conversion price are material considerations for existing shareholders.
FAQ
What is the current stock price of Cyclacel Phar Pr (CYCCP)?
What is the market cap of Cyclacel Phar Pr (CYCCP)?
What is the primary focus of Cyclacel Pharmaceuticals?
How does Cyclacel generate its revenue?
What are the main drug candidates in Cyclacel’s pipeline?
What is the mechanism of action of Cyclacel's therapies?
How does Cyclacel integrate precision medicine into its strategy?
In which therapeutic areas does Cyclacel operate?
How is Cyclacel positioned within the competitive landscape?
What should investors know about Cyclacel’s business model?
